Skip to main content

Pulmozyme Side Effects

Generic name: dornase alfa

Medically reviewed by Last updated on Mar 14, 2024.

Note: This document contains side effect information about dornase alfa. Some dosage forms listed on this page may not apply to the brand name Pulmozyme.

Applies to dornase alfa: inhalation solution.

Serious side effects of Pulmozyme

Along with its needed effects, dornase alfa (the active ingredient contained in Pulmozyme) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dornase alfa:

More common

Other side effects of Pulmozyme

Some side effects of dornase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to dornase alfa: inhalation solution.


Very common (10% or more): Rash (up to 12%)

Rare (less than 0.1%): Urticaria[Ref]


Very common (10% or more): Chest pain (up to 25%)[Ref]


Very common (10% or more): Fever (up to 32%), voice alteration (up to 18%)[Ref]


Very common (10% or more): Pharyngitis (up to 40%), rhinitis (up to 30%), dyspnea (up to 17%)

Common (1% to 10%): Laryngitis, Force Vita Capacity (FVC) decreased of 10% of predicted

Rare (less than 0.1%): Chest pain (pleuritic/non-cardiac), dysphonia, pulmonary function tests decreased[Ref]


Common (1% to 10%): Dyspepsia[Ref]


Common (1% to 10%): Development of serum antibodies (2% to 4%)[Ref]


Common (1% to 10%): Conjunctivitis[Ref]


1. Bryson HM, Sorkin EM (1994) "Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis." Drugs, 48, p. 894-906

2. Witt DM, Anderson L (1996) "Dornase alfa: a new option in the management of cystic fibrosis." Pharmacotherapy, 16, p. 40-8

3. (2001) "Product Information. Pulmozyme (dornase alfa)." Genentech

4. Cerner Multum, Inc. "UK Summary of Product Characteristics."

5. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.